Praxis Precision Medicines (PRAX) Earnings Analysis
Praxis Precision Medicines (PRAX) next reports earnings on 2026-08-03, consensus EPS -3.66837 USD. Last quarter (2026-05-07) it beat with EPS -3.2 USD vs -3.58 USD est (+10.6%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -23.31.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PRAX next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -3.66837 USD |
| Revenue estimate | 0.00B |
PRAX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -3.2 USD | -3.58 USD | +10.6% | Beat |
| 2026-02-19 | -3.5 USD | -3.12593 USD | -12% | Miss |
| 2025-08-04 | -3.31 USD | -3.4 USD | +2.6% | Beat |
| 2025-05-02 | -3.29 USD | -3.2 USD | -2.8% | Miss |
| 2025-02-28 | -2.94 USD | -2.76 USD | -6.5% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
PRAX valuation and analyst view
| Trailing P/E | -23.31 |
|---|---|
| Trailing EPS | -11.30514 USD |
| Price / book | 6.39 |
| Dividend yield | 0.00% |
| Market cap | 6.53B |
| Analyst consensus | Buy (12 buy / 3 hold / 1 sell) |
| Avg price target | 587.86 USD |
Related research pages
Frequently asked questions
When is Praxis Precision Medicines (PRAX)'s next earnings date?
Praxis Precision Medicines is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -3.66837 USD and revenue estimate of 0.00B.
Did PRAX beat earnings last quarter?
In its 2026-05-07 report, PRAX posted EPS of -3.2 USD versus a -3.58 USD estimate — a beat of 10.6%.
What is PRAX's earnings track record?
Over the last 5 reported quarters with consensus data, PRAX beat estimates 2 times (40%).
What is PRAX's current P/E ratio and EPS?
PRAX trades at a trailing P/E of -23.31 on trailing EPS of -11.305136659576599 USD.
What do analysts rate PRAX?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 12 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 587.86 USD.